Share Price:

APNASPENAspen Pharmacare Hldgs15105397 (2.70%)

Aspen is in a closed period from 1st July 2026 until the publication of the annual results on the JSE SENS platform on the 2nd September 2026.

Developing future capability starts with investing in people

That commitment was recently brought to life through the participation of our Group Regulatory Specialist, Nabila Essack, in an international training and development programme focused on vaccine manufacturing and regulation.
Screenshot
The programme includes visits to leading organisations in Germany and provides participants with exposure to global best practices, industry collaboration, and advanced approaches to pharmaceutical manufacturing.
 
For Nabila, the opportunity carries particular significance.
 
“Access to vaccines on the African continent has been a long-standing challenge and being part of Aspen’s vaccine manufacturing journey only makes this opportunity especially meaningful,” she said.
 
“I am incredibly grateful for this opportunity to represent Aspen on this training and development initiative.”
 
Ahead of her departure, Nabila met with Branson Bosman, Executive: Workforce Development & Strategic Engagement, at Aspen’s Gqeberha facility.
 
Reflecting on the importance of opportunities such as these, Branson said:
 
“As an industry, we often speak about localisation, sustainability, future talent and advanced manufacturing capability. These ambitions only become a reality when people are given access to meaningful development opportunities, global exposure and the chance to learn from others.”
 
“The future of pharmaceutical manufacturing in South Africa will depend on exactly these kinds of investments in people. The knowledge, networks and experience gained through opportunities such as this contribute not only to individual growth, but to the long-term capability of our industry.”
 
Nabila’s participation reflects Aspen’s commitment to developing talent, strengthening capability and creating opportunities that support both individual growth and the future of pharmaceutical manufacturing.
 
We wish Nabila every success during the remainder of the programme and look forward to the insights and experience she will bring back to Aspen.

 

Facebook
Twitter
LinkedIn

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: